News Releases Keyword Search Year None2026202520242023202220212020201920182017201620152014 Mar 27, 2026 Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) Feb 26, 2026 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress Feb 23, 2026 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Jan 05, 2026 Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference Print Page RSS E-mail Alerts Contact
Keyword Search Year None2026202520242023202220212020201920182017201620152014 Mar 27, 2026 Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) Feb 26, 2026 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress Feb 23, 2026 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Jan 05, 2026 Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Mar 27, 2026 Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Feb 26, 2026 Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
Jan 05, 2026 Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
